Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as...
For the better part of 2019, the shares of QUOTIENT LTD - NASDAQ: QTNT have found themselves range-bound trading within the $8 - $11 zone, while seemingly continuing to build and work on its long drawn base as is evidenced in the Daily chart above.
While further work is in order, QTNT remains in decent technical shape as the stock presently finds itself trading...
Following my ideas redarding #cellectis. A promising french biotech company that already celebrates hugh success with "their" ucart19 against leukemia. Check out my thoughts and join the conversatioin.
- Double bottom which is normally an indicator for a reversal.
- higher high and higher low
- Oversold Stoch RSI (4hr)
We have a good shorting Opp here. Its showing signs of reversal on most timeframes especially the larger ones such at the Month, Week and Daily.
Noone can see 3-4 years into the future right? Well I'm no different so dont take this as financial advice more of just a hey this looks ok to me sort of thing. Ive taken the time to give you a Fan, a Triangle, and...
Hi there. Price is forming a continuation pattern to the downside. Wait for the price to complete the pattern and watch strong price action for sell.
For longer term, wait for the price to hit the bottom of the bigger pattern and watch strong price action for buy.
m Honestly ot sure i sold at 64 last run when i said load up in my post nad made bak then i had a huge position again at 39 when it comes down and sold at 46.... m thinking maybe 48 because of constellation brands price purchasing it at $48
TDOC medical billing software showing good entry per DPO and CCI from recent decline in value. Good CAGR rate, no Div., positive, near 50% Earnings growth rate the last 5-yr. and nearing profitability, not expected until 2020-2021.
4.4B company in medical billing
Nov 5th, 3:12 pm
$PEN Q3 top line beat of $111.8M vs consensus $102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M
Nov 6th, 9:15 am
$PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for $JNJ $MDT or even $EW
Wells Fargo med-tech analyst Larry Biegelsen has been...
Watch CCI momentum with MACD here. . . future profits and earnings TBD. Await patents and studies. Expect they'll eventually have to sell the farm here to pay for all the cannabis / hemp studies. Ent Value / Mkt Value is 1.02. A new medical advisory board for new medical products. One patent issued 2017 for treatment of neurobahaviors and could lead to...
watching for entry, pulse, dead cat falling wedge for 3rd cycle (2014, 2016, 2018)...TBD
About: Terra Tech Corp. operates as a vertically integrated cannabis-focused agriculture company. The company operates in two segments, Herbs and Produce Products; and Cannabis Dispensary, Cultivation and Production. The Herbs and Produce Products segment offers hydroponic...